• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

    10/25/24 12:19:29 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTC alert in real time by email
    SC 13G/A 1 SXTC_SC13G.txt SXTC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* China SXT Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.08 par value per share (Title of Class of Securities) G2161P140 (CUSIP Number) John Fife, 303 E Wacker Dr, Suite 1040 Chicago, IL 60601 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 25, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) X Rule 13d-1(c) ? Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).? CUSIP No. G2161P140 13G Page 2 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Streeterville Capital LLC 85-2954598 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Utah NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 405,837 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 405,837 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 405,837 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99% (*) 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES * Reporting Person Streeterville Capital LLC (?Streeterville?) has rights under a Convertible Promissory Note dated March 27, 2024 to own an aggregate number of shares of the Issuer?s common stock which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's common stock beneficially owned by Streeterville as of the date of this filing was 405,837 shares, which is 9.99% of the 4,062,435 shares outstanding on October 22, 2024 (as reported in the Issuer's Form F-3 filed on that date). ? CUSIP No. G2161P140 13G Page 3 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Streeterville Management LLC 85-3223919 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 405,837 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 405,837 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 405,837 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99% (*) 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES * Reporting Person Streeterville Management, LLC is the Manager of reporting person Streeterville. Streeterville.has rights under a Convertible Promissory Note dated March 27, 2024 to own an aggregate number of shares of the Issuer?s common stock which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's common stock beneficially owned by Streeterville as of the date of this filing was 405,837 shares, which is 9.99% of the 4,062,435 shares outstanding on October 22, 2024 (as reported in the Issuer's Form F-3 filed on that date). ? CUSIP No. G2161P140 13G Page 4 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) John M. Fife 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 405,837 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 405,837 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 405,837 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99% (*) 12. TYPE OF REPORTING PERSON (see instructions) IN FOOTNOTES * John M. Fife is the sole member of Streeterville Management LLC, which is the Manager of Reporting Person Streeterville. Streeterville.has rights under a Convertible Promissory Note dated March 27, 2024 to own an aggregate number of shares of the Issuer?s common stock which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's common stock beneficially owned by Streeterville as of the date of this filing was 405,837 shares, which is 9.99% of the 4,062,435 shares outstanding on October 22, 2024 (as reported in the Issuer's Form F-3 filed on that date). ? CUSIP No. G2161P140 13G Page 5 of 8 Pages Item 1. (a) Name of Issuer China SXT Pharmaceuticals, Inc. (b) Address of Issuer?s Principal Executive Offices 178 Taidong Rd North Taizhou, Jiangsu, China Item 2. (a) Name of Person Filing This report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife with respect to the shares of Common Stock, $0.08 par value per share, of the Issuer that are directly beneficially owned by Streeterville Capital LLC and indirectly beneficially owned by the other reporting and filing persons. (b) Address of the Principal Office or, if none, residence 303 East Wacker Drive, Suite 1040, Chicago, IL 60601 (c) Citizenship Streeterville Capital LLC is a Utah limited liability company. Streeterville Management LLC is a Utah limited liability company. John M. Fife is a United States citizen. (d) Title of Class of Securities Common Stock, $0.08 par value per share (e) CUSIP Number G2161P140 Item 3. If this statement is filed pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ? Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ? Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ? Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ? Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) ? An investment adviser in accordance with ?240.13d-1(b)(1)(ii)(E); (f) ? An employee benefit plan or endowment fund in accordance with ?240.13d- 1(b)(1)(ii)(F); (g) ? A parent holding company or control person in accordance with ?240.13d- 1(b)(1)(ii)(G); (h) ? A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ? A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ? Group, in accordance with ?240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 405,837 (b) Percent of class: 9.99% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 405,837 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 405,837 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ? . N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. G2161P140 13G Page 8 of 8 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 10/25/2024 Date Streeterville Capital LLC /s/ John Fife Signature John Fife/President Name/Title Streeterville Management LLC /s/ John Fife Signature John Fife/President Name/Title John M. Fife /s/ John Fife Signature John Fife Name/Title
    Get the next $SXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

      TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that the Company received a written notification (the "Compliance Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Ru

      3/17/25 8:30:00 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Announces Share Consolidation

      TAIZHOU, China, Feb. 21, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the "Share Consolidation"). The Company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of th

      2/21/25 12:35:28 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

      Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC) announced today that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. Under the Nasdaq List

      10/7/24 4:15:00 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    SEC Filings

    See more
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/19/25 8:00:24 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

      6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/13/25 11:30:25 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/7/25 7:58:31 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      10/25/24 12:19:29 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      8/15/24 9:45:36 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc. (Amendment)

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      5/31/24 10:36:52 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

      XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

      4/25/23 8:30:00 AM ET
      $BON
      $SXTC
      $WSG
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Services-Misc. Amusement & Recreation